Ivantis, Inc.

25 articles about Ivantis, Inc.

• Alcon Completes Acquisition of Ivantis, Inc., Bringing Hydrus Microstent into Its Global Surgical Portfolio

  1/10/2022

  Alcon announced the closing of its previously announced acquisition of Ivantis®, developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery device designed to lower eye pressure for open-angle glaucoma patients in connection with cataract surgery.

• Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma

  12/15/2021

   Ivantis Inc., developer of the novel Hydrus® Microstent, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent cataract surgery.

• Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data

  11/15/2021

  Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone.

• Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.

  9/15/2021

  Ivantis to Pay $60 Million and Ongoing Double-Digit Royalty to Glaukos

• Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use

  3/4/2021

  Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery device designed to lower eye pressure for open-angle glaucoma patients, announced the first-ever release of five-year follow-up data from its HORIZON pivotal trial.

• Ivantis Recognized For Innovation, Excellence And Company Culture

  12/16/2020

  Fast-Growing Medical Device Company Developing New Treatment Options for Glaucoma Patients Receives Numerous Awards & Recognition from Ernst & Young, American Academy of Ophthalmology, Red Herring and Others

• Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines

  11/17/2020

  Ivantis' Commitment to Scientific Rigor Earns Primary Open-Angle Glaucoma Preferred Practice Pattern Designation and Fifth Publication in the Journal Ophthalmology

• Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstent

  10/10/2019

  Largest Single-Device Ophthalmic Registry Includes Nearly 3,000 Eyes with 700+ Stand-Alone Glaucoma Procedures

• Ivantis Announces Groundbreaking 3 Year Results from FDA Clinical Trial; First Device in Minimally Invasive Glaucoma Surgical (MIGS) Category to Demonstrate Significant Long Term Reduction of Severe Major Surgeries for Glaucoma Patients

  5/2/2019

  First study of any kind showing a MIGS device achieving a statistically significant reduction in secondary incisional surgery; over 70% of patients remain free of medications

• Ivantis Announces Publication of Landmark Comparative MIGS Clinical Trial Results in Leading Ophthalmic Journal

  4/23/2019

   Ivantis Inc., developer of the Hydrus® Microstent, announced today that the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS) were accepted into the journal Ophthalmology.

• Ivantis Announces 24-Month Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial

  3/14/2019

  International Multi-center Study Compares Effectiveness of the Hydrus® Microstent to Two Glaukos iStent® Trabecular Micro-Bypass Stents in Standalone Glaucoma

• Ivantis Announces FDA Approval for Its Innovative Hydrus® Microstent Device for Minimally Invasive Glaucoma Surgery (MIGS)

  8/13/2018

  The Next-Generation MIGS Device, Implanted During Cataract Surgery, Lowers Intraocular Pressure in Patients with Glaucoma, a Leading Cause of Blindness

• Ivantis Announces Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial

  4/16/2018

  International Multi-center Study Compares Effectiveness of the Hydrus® Microstent to Two iStent® Trabecular Micro-Bypass Stents in Standalone Glaucoma

• Ivantis FDA Clinical Trial of the Hydrus Microstent for Minimally Invasive Glaucoma Surgery (MIGS) Meets Endpoints, Exceeds Outcomes of Past MIGS Trials

  11/13/2017

  Outcomes exceed those of any MIGS pivotal trial to date.

• Ivantis Completes Pre-Market Approval Submission for the Hydrus Microstent for Minimally Invasive Glaucoma Surgery

  11/1/2017

  Ivantis announced today that it has submitted its final Pre-Market-Approval module to the FDA for market approval.

• Ivantis Nabs $25 Million Series C for Hydrus Microstent

  1/10/2017

• Ivantis, Inc. Completes Enrollment In Pivotal HYDRUS IV Glaucoma Study Of The Hydrus Microstent

  4/17/2015

• Ivantis, Inc. Announces HYDRUS II Glaucoma Study Met Primary Endpoint In A Randomized Controlled Trial At Two Years

  10/21/2014

• SoCal's Ivantis, Inc. Reels In Another $25 Million; Increasing Series B Funding To $71 Million

  9/23/2014

• Ivantis, Inc. Reels In $46.5 Million; Wins FDA Approval to Expand US Pivotal Trial For Novel Glaucoma Device

  1/13/2014